INFORMATION IN THIS EXHIBIT IDENTIFIED BY BRACKETS IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CASI PHARMACEUTICALS, INC. IF...Investment Agreement • November 9th, 2020 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
THIS INVESTMENT AGREEMENT (this “Agreement”), dated September 22, 2020 (Beijing time, the “Execution Date”), is entered into by and between:
INFORMATION IN THIS EXHIBIT IDENTIFIED BY BRACKETS IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CASI PHARMACEUTICALS, INC. IF...Supplementary Agreement to the Exclusive License Agreement • November 9th, 2020 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Hong Kong
This Supplementary Agreement to the Exclusive License Agreement (this “Agreement”), is entered into as of September 29, 2020 (Beijing Time, “Effective Date”), by and between:
